Next Phase Newsletter

A global angel investment group was created to leverage cross-pacific business opportunities by investing in early stage life science and healthcare companies, with an Asia connection. The firm invests in companies that are interested in performing development work in China, or commercializing their products in Asia;  the firm makes use of relationships with Asia-based life science service providers to guide portfolio companies through the development process , and also assists companies with the Chinese regulatory process. The firm is pre-venture capital and can contribute business, scientific and regional expertise to companies to improve probability for success. 
 
The firm will consider opportunities across the life science space, and is primarily focused on diagnostics and devices but also invests in therapeutics and life science tools.  The firm generally invests in companies with products with strong animal data, and which are addressing a significant health problem in China (such as cancer, cardiovascular and metabolic diseases, infectious diseases, and also CNS disorders in some circumstances).  Companies which have already attained approval in a market outside China may be of interest. 
 
The firm invests in early stage deals.  The firm only invests in companies that are interested in performing development work in China, or commercializing their products in China; the firm makes use of relationships with China-based life science service providers to guide portfolio companies through the development process and obtain matching government funds in China, and also assists companies with the Chinese regulatory process. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

An impact investor focused on pediatric indications is willing to invest in companies in therapeutics, diagnostics, medical devices or digital health that help improve pediatric care. As an impact fund, the firm donates 10% of the General Partner’s Carry Interest to fund pediatric research. The firm generally makes initial investments of $3-5M and will invest globally. The firm looks to invest in 12-15 companies out of their first fund. 
 
Within pediatric indications, the firm is interested in Oncology, Infectious Diseases and select Rare/Orphan indications. The firm will consider any technology that helps move care forward in these areas, either directly, as a therapeutic or other treatment device or diagnostic, or indirectly, as a digital health technology that helps support care or complements treatment. For therapeutics, the firm will invest in companies that are 12-18 months from IND. For diagnostics and medical devices, the firm would like to see a proof of concept or prototype. For digital health, some post pilot sales or evidence of market traction is preferred, as is a partnership with a strategic partner, with validation of the technology. 
 
The firm can lead or co-invest, and looks to be a board observer for every portfolio company. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

Established in 2021, a USA-based venture capital firm is specialized in investments within the neurotech and psychedelics sectors. The fund actively participates in pre-seed to seed financing rounds, with an initial investment averaging around $200k and the possibility of subsequent investments. The firm actively seeks opportunities in the United States. 
 
The firm actively seeks opportunities in psychoactive therapeutics, CNS therapeutics, neurotech, and techbio. The firm has a neuro focus, and is interested in technologies/products related to CNS disorders, neurodegenerative diseases, neurostimulation and modulation, psychoactive pharmacology, etc. The firm typically invests in drug/therapeutics and medical devices but not so much in digital health. Additionally, the firm looks for cutting edge technologies that demonstrate true, step change or cornerstone innovation instead of incremental improvements on best-in-class technologies. 

The firm is an active investor that supports their portfolio companies with their network and resources. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A corporate venture capital fund invests globally in technologies with potential to impact mortality rates at scale by improving healthcare quality and outcomes to support the corporation’s goal of helping save 1M lives annually by 2030. This fund prioritizes technologies that address acute, time-critical conditions and makes investments internationally. The firm will invest up to $5M USD for their first check with capital reserved to follow on. The firm currently has 12 portfolio companies and is actively deploying capital. 
 
The firm invests solely in medical devices, diagnostics, and digital health. The fund does not invest in therapeutics, biotech, pharma, and CROs. The fund looks at acute, time-critical areas of healthcare and is interested in solutions that support prevention, earlier identification and intervention, and improved therapeutics for these conditions. Key areas of focus include, but are not limited to cardiovascular care, sepsis, stroke, trauma and surgery, maternal and neonatal care, emergency medicine, and healthcare education & training. 
 
The firm can act both as a lead and co-investor. The firm needs to see committed and full-time teams with demonstrated product market fit. The fund invests in pre- and post- FDA approval companies, but companies should have an MVP and licensed IP where relevant. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

An early-stage venture capital firm was founded in 2010 and based in the US. The firm is a generalist fund, looking to expand its footprint in life sciences, specifically data, diagnostics, and therapeutics in oncology.  The firm focuses on Pre-Seed, Seed, and Series A investments. Typical check size ranges from $500k-5M USD, leading rounds. The firm focuses on companies in the US. 
 
The firm invests in data, diagnostics and therapeutics, with a strong preference in oncology. The firm was one of the first institutional investors in Tempus, an AI-driven data and diagnostics platform, and Pathos, an AI-driven clinical stage therapeutics platform in oncology.  Within therapeutics, companies should be pre-Phase II and for data and diagnostics companies, in-development stages. 
 
The firm does not require to take a board or observer seat but often will. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A venture capital firm founded and headquartered in Taiwan is overall focused on investing in biotech and tech-related companies such as AI, biotech, medical device, pharma, fintech, semiconductors, smart manufacturing, etc. The firm is stage agnostic, however, within life science and healthcare, the firm is also focusing on early-stage companies from Pre-Series A to Series B. Typical check sizes range from $1M-10M, although usually it will be $3M-5M to start. The firm participates in co-investing, but 60-70% of the time, the firm will lead. The firm is looking at companies in the U.S., Japan, Taiwan, and Central Eastern Europe, with the goal of creating a cross-border ecosystem that helps healthcare and biotech companies thrive. The firm is also willing to help later-stage companies with commercialization and connect with Taiwanese partners and key players in the U.S. 
 
The firm invests in fundamental science driven companies with a technology focus. The main sectors the company focuses on are chronic disease management/treatment, AI and/or digital health, and service-based companies. Main indication areas include oncology, metabolic diseases, and autoimmune diseases, however indication areas are not limited to those listed. The firm is also open to orphan diseases, however, it has to be a platform that addresses orphan diseases to validate the technology. The firm looks at in-development and clinical stages as well as pre-approval, but they may not be interested in very early stages. For drugs, the firm requires proof of biology with an established animal model data. 
 
The firm may invest in young teams to grow with them, however most of the time, the firm prefers companies to have an experienced team in place. The firm also requires taking a board seat, if not, at least an observer seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A venture capital firm specialized in life sciences and medical technology, managing both RMB and USD funds with a total size of $1.5B, is operated by a professional team with diversified and profound industry backgrounds, having made over 90 investments with high growth potential since 2014. Typical Allocations Size of the firm’s RMB fund is 30MM-150MM in RMB, and up to 200MM in RMB; for the USD fund, the firm invests $5-10MM+ on average, and up to $20MM. 
 
The firm is open to investing in general Bio-medical industries globally, including diagnostics, medical devices, therapeutics and AI in the healthcare service platform. Especially, the firm is interested in medical imaging, minimally invasive diagnosis specially IVD and treatment, diagnostic reagents and mobile health. The firm prefers diagnostics companies that are at the growth stage but are looking for biotech companies in the seed stage. The firm is not interested in small molecules nor antibodies for now. 
 
The firm prefers companies that are tech-driven, commercially viable and are able to solve the real problem. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.